在放射性耐受性甲状腺癌中针对性基因融合的下一代测序:一项多中心研究
Endocrine-related cancer
|June 26, 2025
概括
针对性基因融合在耐放射性的甲状腺癌中普遍存在,特别是在年轻患者中. 分子分析有助于识别准确疗法的候选者,如氨酸激酶抑制剂.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 耐放射性的甲状腺癌是一个重大的临床挑战.
- 识别可操作的分子变化对于个性化治疗策略至关重要.
研究的目的:
- 确定抗放射性甲状腺癌患者中可向基因融合的患病率和临床意义.
- 评估分子分析对指导治疗决策的有用性.
主要方法:
- 一个多中心的回顾性队列研究,涉及111名患者.
- 针对性下一代测序用于分子分析.
主要成果:
- 52.3%的人患有BRAFV600E突变,22.5%的人患有RAS突变,18%的人患有基因融合 (RET,NTRK,BRAF).
- 在30.8%的野生型BRAF患者中发现了可向的基因融合.
- 基因融合的患者年轻,经常患有经典的乳头状甲状腺癌.
结论:
- 一个逐步的分子测试方法,从BRAF分析开始,然后是基因融合的下一代测序,是合理的.
- 分子分析对于识别符合准确治疗条件的患者,包括氨酸激酶抑制剂,以及指导耐火性甲状腺癌的个性化治疗是有价值的.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


